News
Q2 2025 Management View CEO Leonard S. Schleifer reported "Regeneron delivered a strong second quarter, driven by durable ...
If you're looking to put cash into two fantastic biotech stocks that Wall Street seems particularly bullish on, there's one ...
Regeneron Pharmaceuticals, Inc. reported second-quarter earnings that significantly exceeded analyst expectations, with adjusted earnings per share reaching $12.89 compared to the $8.43 consensus ...
Q2 2025 Earnings Call Transcript August 1, 2025 Regeneron Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is ...
On July 2, linvoseltamab-gcpt (Lynozyfic; Regeneron) received an accelerated approval from the FDA in relapsed/refractory ...
Regeneron has received a second complete response letter from the FDA for odronextamab and anticipates delays for Eylea HD ...
Regeneron announced FDA accelerated approval for Lynozyfic™ to treat advanced multiple myeloma in heavily pre-treated patients. Quiver AI Summary Regeneron Pharmaceuticals announced that the FDA ...
Second quarter 2025 revenues increased 4% to $3.68 billion versus second quarter 2024Dupixent® global net sales (recorded by Sanofi) increased 22% to $4.34 billion EYLEA HD® U.S. net sales increased ...
Regeneron Pharmaceuticals delivered strong Q2 results and made net progress with its commercial portfolio and pipeline. Click ...
Following the FDA approval of linvoseltamab (Lynozyfic; Regeneron) for heavily pretreated multiple myeloma, Sundar Jagannath, MBBS, highlights its potential for earlier use, increased accessibility, ...
On July 2, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Regeneron's Lynozyfic ...
--Regeneron Pharmaceuticals, Inc. today announced that the European Commission has granted conditional marketing approval of Lynozyfic™ to treat adults with relapsed and refractory multiple myeloma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results